196 related articles for article (PubMed ID: 12189532)
1. Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
Vahdat LT; Balmaceda C; Papadopoulos K; Frederick D; Donovan D; Sharpe E; Kaufman E; Savage D; Tiersten A; Nichols G; Haythe J; Troxel A; Antman K; Hesdorffer CS
Bone Marrow Transplant; 2002 Aug; 30(3):149-55. PubMed ID: 12189532
[TBL] [Abstract][Full Text] [Related]
2. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
[TBL] [Abstract][Full Text] [Related]
3. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle.
Bashey A; Corringham S; Garrett J; Lane TA; Gilpin EA; Corringham RE; Law P; Ho AD
Bone Marrow Transplant; 2000 Mar; 25(5):519-24. PubMed ID: 10713629
[TBL] [Abstract][Full Text] [Related]
6. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W
Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160
[TBL] [Abstract][Full Text] [Related]
7. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation.
Demirer T; Uysal VA; Ayli M; Genc Y; Ilhan O; Koc H; Dagli M; Arat M; Gunel N; Fen T; Dincer S; Ustael N; Yildiz M; Ustun T; Seyrek E; Ozet G; Muftuoglu O; Akan H
Bone Marrow Transplant; 2003 May; 31(9):755-61. PubMed ID: 12732881
[TBL] [Abstract][Full Text] [Related]
8. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
Fontelonga A; Kelly AJ; MacKintosh FR; Hall S; Monroe P; Wilson GS; Shaft D; Ruthven A; Ascensao JL
Bone Marrow Transplant; 1997 May; 19(10):983-8. PubMed ID: 9169642
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
Vahdat LT; Papadopoulos K; Balmaceda C; McGovern T; Dunleavy J; Kaufman E; Fung B; Garrett T; Savage D; Tiersten A; Ayello J; Bagiella E; Heitjan D; Antman K; Hesdorffer C
Clin Cancer Res; 1998 Jul; 4(7):1689-95. PubMed ID: 9676843
[TBL] [Abstract][Full Text] [Related]
10. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
Elias AD; Ibrahim J; Richardson P; Avigan D; Joyce R; Reich E; McCauley M; Wheeler C; Frei E
Biol Blood Marrow Transplant; 2002; 8(4):198-205. PubMed ID: 12017145
[TBL] [Abstract][Full Text] [Related]
11. Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer.
Wandt H; Birkmann J; Denzel T; Schäfer K; Schwab G; Pilz D; Egger H; Both A; Gallmeier WM
Bone Marrow Transplant; 1999 Apr; 23(8):763-70. PubMed ID: 10231137
[TBL] [Abstract][Full Text] [Related]
12. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.
Antman K; Ayash L; Elias A; Wheeler C; Schwartz G; Mazanet R; Tepler I; Schnipper LE; Frei E
J Natl Cancer Inst Monogr; 1994; (16):91-4. PubMed ID: 7528031
[TBL] [Abstract][Full Text] [Related]
13. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer.
Biron P; Durand M; Roché H; Delozier T; Battista C; Fargeot P; Spaeth D; Bachelot T; Poiget E; Monnot F; Tanguy ML; Curé H
Bone Marrow Transplant; 2008 Mar; 41(6):555-62. PubMed ID: 18037940
[TBL] [Abstract][Full Text] [Related]
14. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
[TBL] [Abstract][Full Text] [Related]
16. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.
Stadtmauer EA; O'Neill A; Goldstein LJ; Crilley PA; Mangan KF; Ingle JN; Brodsky I; Martino S; Lazarus HM; Erban JK; Sickles C; Glick JH
N Engl J Med; 2000 Apr; 342(15):1069-76. PubMed ID: 10760307
[TBL] [Abstract][Full Text] [Related]
17. Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study.
García-Rayo S; Pérez-Calvo J; Martín-Algarra S; Martínez-Monge R; Fernández-Hidalgo O; Subirá L; Martínez-Aguillo M; Rebollo J; Azinovic I; Brugarolas A
Bone Marrow Transplant; 2001 Aug; 28(3):235-42. PubMed ID: 11535990
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer.
deMagalhaes-Silverman M; Bloom E; Lembersky B; Lister J; Pincus S; Rybka W; Voloshin M; Wilson J; Ball E
Clin Cancer Res; 1997 Feb; 3(2):193-7. PubMed ID: 9815672
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of repetitive cycles of dose-intense carboplatin plus paclitaxel chemotherapy and peripheral blood stem cells in metastatic breast cancer.
Ford C; Spitzer G; Reilly W; Adkins D
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-81-S17-86. PubMed ID: 9374101
[TBL] [Abstract][Full Text] [Related]
20. Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC).
Meisenberg BR; Miller WE; McMillan R
Bone Marrow Transplant; 1996 Dec; 18(6):1087-93. PubMed ID: 8971377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]